Nordisk Pharma ApS: Financial statements 2025
CVR: 42852287
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Nordisk Pharma ApS (CVR 42852287) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 365,248 and a net result of DKK 207,225 compared with DKK 425,521 the year before. That is a decrease of 33.9% compared with the year before. Equity in the 2025 report amounted to DKK 1,216,729. The solvency ratio was 84.2%.
- Gross Profit
- DKK 365,248
- Profit/Loss
- DKK 207,225
- Equity
- DKK 1,216,729
- Total Assets
- DKK 1,445,878
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 365 t. | 207 t. | 1.2 mio. | 0 |
| 2024 | - | 553 t. | 426 t. | 1 mio. | 0 |
| 2023 | - | 332 t. | 263 t. | 584 t. | 0 |
Official annual report
How creditworthy is Nordisk Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Nordisk Pharma ApS has published its annual report for 2024. Gross profit came to DKK 552,864, and the net result was DKK 425,521.
About Nordisk Pharma ApS
Nordisk Pharma ApS is a Danish company of the type Anpartsselskab based in Vallensbæk, founded in 2021. The company is registered under the industry Fremstilling af medicinske og dentale instrumenter samt udstyr hertil. The management consists of Sayed Edris Sadat and Sanad Emad Hussein Al Bidany. The company is owned by Nordisk Pharma Holding ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 365,248 and a net result of DKK 207,225 compared with DKK 425,521 the year before. Equity in the 2025 report amounted to DKK 1,216,729.